Zhijian ‘James’ Chen, Ph.D.
Strategic and Scientific Advisor
Investigator of Howard Hughes Medical Institute
Professor in the Department of Molecular Biology at the University of Texas Southwestern Medical Center at Dallas
Director of Inflammation Research Center and George L. MacGregor Distinguished Chair in Biomedical Science at UT Southwestern
Zhijian 'James' Chen is distinguished scientist, academician and professor in the fields of immunology, inflammation research and biomedical science.
Prior to establishing his academic research laboratory, Chen was a senior scientist at ProScript Inc. where he helped discover the proteasome inhibitor VELCADE, a medicine used for the treatment of multiple myeloma. After joining UT Southwestern in 1997, Chen discovered the regulatory role of ubiquitination in protein kinase activation in the NF-kB and MAP kinase pathways. In addition, he discovered the Mitochondrial Antiviral Signaling (MAVS) protein that reveals a new role of mitochondria in immunity. More recently, Chen discovered cyclic GMP-AMP synthase (cGAS) as a cytosolic DNA sensor and a new cyclic di-nucleotide signaling pathway that mediate innate immune responses in animal cells. For his work, Chen has received numerous honors including the National Academy of Science Award in Molecular Biology (2012), the American Society of Biochemistry and Molecular Biology (ASBMB) Merck Award (2015), the Lurie Prize in Biomedical Sciences from the Foundation of NIH (2018), the Breakthrough Prize in Life Sciences (2019), and the Switzer Prize (2019). Chen is a member of the National Academy of Sciences.